# Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)

Study · id `cardio:ct-nct06005259` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06005259](<https://clinicaltrials.gov/study/NCT06005259>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06005259

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.

## Technical summary

Registry record NCT06005259. Randomized; triple masking; primary purpose prevention. Start 2023-10-01 (anticipated); primary completion 2025-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 264 participants (planned count; ClinicalTrials.gov record NCT06005259, source copy `cardio:ctgov-nct06005259-2023-08-22`, retrieved 2026-10-26)
- Planned start: 2023-10-01 (anticipated) (ClinicalTrials.gov record NCT06005259, source copy `cardio:ctgov-nct06005259-2023-08-22`, retrieved 2026-10-26)
- Primary completion: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT06005259, source copy `cardio:ctgov-nct06005259-2023-08-22`, retrieved 2026-10-26)
- Completion: 2025-12-01 (anticipated) (ClinicalTrials.gov record NCT06005259, source copy `cardio:ctgov-nct06005259-2023-08-22`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT06005259, source copy `cardio:ctgov-nct06005259-2023-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06005259-2023-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
- Acronym: SPIROTOX
- Condition: Cardiotoxicity
- Condition: Neoplasms
- Condition: Chemotherapy Effect
- Condition: Heart Failure
- Intervention (Drug): Spironolactone
- Intervention (Drug): Placebo
- Lead sponsor: University of Sao Paulo
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo (`cardio:org-university-of-sao-paulo`)

## Provenance

Content hash: 24aa5f63e7b350f0f0e6f0e41aca42129ae6fe8cf148d722334bd7cd991a5271
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
